Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of INSTILADRIN in BCG-Refractory NMIBC
NCT01687244Phase 2Completed
- Sponsor
- FKD Therapies Oy
- Start
- Sep 2012
- Primary completion
- Oct 2015
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
01
Overview
A Phase 2 trial of nadofaragene firadenovec in non-muscle-invasive bladder cancer (NMIBC), sponsored by FKD Therapies Oy. Started Sep 2012; status: completed.
02
Drugs
nadofaragene firadenovec
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT01687244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01687244.